Motus GI Holdings, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Motus GI Holdings, Inc. engages in the development and commercialization of innovative medical technology designed to improve gastrointestinal endoscopy outcomes, primarily focusing on enhancing visualization during colonoscopies. The company's flagship product is the Pure-Vu® System, including the Gen 2 and Gen 4 Colon and EVS Gastro versions, which are disposable, single-use add-on devices compatible with standard colonoscopes that provide integrated irrigation and evacuation to clear poorly prepped colons during procedures. This technology targets gastroenterologists, hospitals, and ambulatory surgery centers in the United States and selected international markets to reduce the rate of delayed or aborted colonoscopies and improve adenoma detection rates. Founded in 2010 and headquartered in Fort Lauderdale, Florida, Motus GI has concentrated on the gastrointestinal endoscopy market by offering its FDA-cleared Pure-Vu System, which received multiple regulatory approvals including 510(k) clearances for both lower and upper GI applications. The company has focused its recent efforts on expanding commercialization in the U.S., successfully ramping up its product launch with double the active customer base ordering disposable sleeves as of early 2024. Motus GI has also engaged in strategic initiatives such as obtaining expanded credit financing and exploring business development opportunities to increase market penetration. In a significant operational change during 2024, Motus GI Holdings underwent a court-supervised asset sale, transferring its core Pure-Vu® System technology to CONMED Corporation for approximately $14 million. This transaction led to the delisting of Motus GI from the Nasdaq exchange and the dissolution of its independent operations. The company's leadership and management were effectively disbanded, and control of the core product intellectual property and commercialization now resides with CONMED. Prior to this transition, Motus GI actively worked on product enhancements and garnered positive clinical results from European studies demonstrating the effectiveness of the Pure-Vu System in improving visualization during colonoscopy for patients with inadequate bowel preparation. Motus GI's product portfolio includes single-use disposable devices designed to be integrated into existing colonoscopy workflows, targeting the GI hospital and ambulatory surgery center segments to address a key clinical challenge in colorectal diagnostics. The company has historically focused on innovation in endoscopic irrigation technology and patent-protected mechanisms to support procedural success, with its recent major changes centering on the divestiture of its assets and transition of operations under a larger medical technology firm, thus marking a strategic exit from direct market participation. Overall, Motus GI Holdings, Inc. positions itself as a specialized medical technology company improving colonoscopy outcomes through advanced device technology, with its latest major development being the acquisition of its core assets by CONMED Corporation in 2024, signaling a major shift from independent commercialization to integration within a broader medical device portfolio. This strategic shift follows several years of regulatory approvals, market introductions, and ongoing efforts to enhance product adoption and commercial success in the gastrointestinal diagnostics sector.
Why Is Motus GI (MOTS) Stock Down 37% Today?
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
Why Is Motus GI (MOTS) Stock Down 44% Today?
Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering
Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon
Motus GI Amends Royalty Agreement
Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors
Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System
New Strong Buy Stocks for July 21st
Motus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical Center
Motus GI Holdings, Inc. (MOTS) Upgraded to Strong Buy: Here's What You Should Know